Riddle M A, Nelson J C, Kleinman C S, Rasmusson A, Leckman J F, King R A, Cohen D J
Yale Child Study Center, New Haven, CT 06510-8009.
J Am Acad Child Adolesc Psychiatry. 1991 Jan;30(1):104-8. doi: 10.1097/00004583-199101000-00016.
The 1990 "package insert" for Norpramin, the Merrell Dow Pharmaceuticals Inc., brand of desipramine, was changed to include the following statement in the Adverse Reactions section, "There has been a report of an 'acute collapse' and 'sudden death' in an eight-year-old (18 kg) male, treated for two years for hyperactivity. There have been additional reports of sudden death in children." The purpose of this commentary is to review what is known about the three reported cases of sudden death and to discuss the implications of these tragedies for children receiving treatment with tricyclic drugs.
1990年，美国家庭用品公司（现称“惠氏公司”）生产的去甲丙咪嗪品牌“Norpramin”的“药品说明书”在“不良反应”部分做出修改，增加了以下声明：“有报告称，一名8岁（体重18公斤）男性因多动症接受了两年治疗，期间出现了‘急性虚脱’和‘猝死’。此外，还有儿童猝死的报告。”本评论的目的是回顾已了解到的三例报告的猝死病例情况，并讨论这些悲剧事件对接受三环类药物治疗的儿童的影响。
